M
Michael Emig
Researcher at Heidelberg University
Publications - 15
Citations - 1481
Michael Emig is an academic researcher from Heidelberg University. The author has contributed to research in topics: Chronic myelogenous leukemia & Imatinib mesylate. The author has an hindex of 9, co-authored 15 publications receiving 1451 citations.
Papers
More filters
Journal ArticleDOI
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders
Amy V. Jones,Sebastian Kreil,Katerina Zoi,Katherine Waghorn,Claire Curtis,Lingyan Zhang,Joannah Score,Rachel Seear,Andrew Chase,Francis H. Grand,Helen E. White,Christine Zoi,Dimitris Loukopoulos,Evangelos Terpos,Elisavet-Christine Vervessou,Beate Schultheis,Michael Emig,Thomas Ernst,Eva Lengfelder,Rüdiger Hehlmann,Andreas Hochhaus,David Oscier,Richard T. Silver,Andreas Reiter,Nicholas C.P. Cross +24 more
TL;DR: It is concluded that V617F is widespread in MPDs and detection of this acquired mutation is likely to have a major impact on the way patients with MPD are diagnosed, as well as serving as an obvious target for signal transduction therapy.
Journal ArticleDOI
Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR.
Michael Emig,Susanne Saussele,H. Wittor,A. Weisser,Andreas Reiter,A. Willer,Ute Berger,Ruediger Hehlmann,Nicholas C.P. Cross,Andreas Hochhaus +9 more
TL;DR: It is concluded that real-time pcr with hybridization probes is a reliable and sensitive method to monitor cml patients after therapy.
Journal ArticleDOI
Loss of p53 impedes the antileukemic response to BCR-ABL inhibition
Hans-Guido Wendel,Elisa de Stanchina,Enrique Cepero,Sagarika Ray,Michael Emig,Jordan S. Fridman,Darren R. Veach,William G. Bornmann,Bayard D. Clarkson,W. Richard McCombie,Scott C. Kogan,Andreas Hochhaus,Scott W. Lowe +12 more
TL;DR: The results identify p53 as a determinant of the response to oncogene inhibition and suggest one way in which resistance to targeted therapy can emerge during the course of tumor evolution.
Journal ArticleDOI
Detection and quantification of residual disease in chronic myelogenous leukemia.
Andreas Hochhaus,A. Weisser,La Rosée P,Michael Emig,Martin C. Müller,Susanne Saussele,Andreas Reiter,Christian Kuhn,Ute Berger,Ruediger Hehlmann,Nicholas C.P. Cross +10 more
TL;DR: New quantitative real time procedures promise to simplify the protocols that are currently in use, but standardization and the introduction of rigorous, internationally accepted controls are required to enable RT-PCR to become a robust and routine basis for therapeutic decisions.
Journal ArticleDOI
Nitro musks are cogenotoxicants by inducing toxifying enzymes in the rat
TL;DR: Both MX and MK were strong inducers of toxifying liver enzymes and seem to be cogenotoxicant for a number of well-known pregenotoxicants in the SOS chromotest.